Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,025.00
-19.6700-1.88%
Post-market: 1,025.250.2500+0.02%19:59 EST
Volume:3.54M
Turnover:3.65B
Market Cap:969.02B
PE:44.66
High:1,055.65
Open:1,050.66
Low:1,023.88
Close:1,044.67
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.62
T/O Rate:0.37%
Dividend:6.00
Dividend Rate:0.59%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:108.28%
ROA:17.60%
PB:40.73
PE(LYR):44.66

Loading ...

Eli Lilly's Intestinal Disease Treatment Mirikizumab Receives Approval in China

Stock News
·
52 mins ago

Eli Lilly: Mirikizumab Approved in China for Treatment of Moderate-to-Severe Crohn's Disease and Ulcerative Colitis - Co Statement

THOMSON REUTERS
·
2 hours ago

Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares

TIPRANKS
·
4 hours ago

Eli Lilly Expands Genetic Medicines Pipeline And Valuation Case With New Deals

Simply Wall St.
·
8 hours ago

Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

Dow Jones
·
10 hours ago

Eli Lilly upgraded to Buy from Hold at Freedom Capital

TIPRANKS
·
10 hours ago

Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market

TIPRANKS
·
14 hours ago

Innovent Biologics Forges Seventh Partnership with Eli Lilly in $8.85 Billion Deal

Deep News
·
Yesterday

Deals of the day -Mergers and acquisitions

Reuters
·
Yesterday

Dow Jones Top Company Headlines at 9 PM ET: Novo Nordisk Escalates Fight Against Hims & Hers | On ...

Dow Jones
·
Yesterday

Top News Today: Stocks Rise as AI, Crypto Fears Subside

Dow Jones
·
Yesterday

Top Midday Stories: Novo Nordisk Sues Hims for Alleged Patent Infringement; Transocean to Acquire Valaris for $5.8 Billion

MT Newswires Live
·
Yesterday

Eli Lilly Shares Climb Over 3% on Acquisition of Immune Cell Engineering Firm Orna Therapeutics

Stock News
·
Feb 09

Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday

Benzinga_recent_news
·
Feb 09

BRIEF-Lilly Q4 Adjusted EPS USD 7.54 Vs. IBES Estimate USD 6.67 (Feb. 4)

Reuters
·
Feb 09

Argus Adjusts Price Target on Eli Lilly and Company to $1,200 From $930, Maintains Buy Rating

MT Newswires Live
·
Feb 09

Eli Lilly Is Maintained at Buy by Deutsche Bank

Dow Jones
·
Feb 09

Lilly To Buy Orna Therapeutics For Up To $2.4 Billion

Reuters
·
Feb 09

Eli Lilly : Argus Research Raises Target Price to $1200 From $930

THOMSON REUTERS
·
Feb 09

Corrected-Eli Lilly & Co. : Morgan Stanley Raises Target Price to $1,313 From $1290 (Not to $1290.00 From $24.20) (Feb 5)

THOMSON REUTERS
·
Feb 09